Strategy to Accelerate Research (STAR)

Launched in 2008, STAR brings together researchers, pharmaceutical companies, and patients to find treatments for CMT.

The progress has been nothing short of amazing.

The CMTA has invested over $16M in recent years and our strategy outlines investments of another $10M in the next few years to help bring CMT drugs and therapies to market.

- We currently have over 50 active research projects with the top labs around the world, all vetted through our advisory board, comprised of 30 of the top CMT scientists from across the globe.
- The CMTA has initiated partnership agreements with more than 30 academic, pharmaceutical, biotech and service companies across three continents. They are leaders in the latest genetic and neurological technologies (such as CRISPR, gene therapy, gene silencing, axon and muscle regeneration). These partners are actively working with the CMTA to develop treatments for the 3 million patients living with CMT.
- We have a network of more than 35 CMT Centers of Excellence, 70 branches, and a partnership with the Inherited Neuropathy Consortium (INC). Through this network we are building patient registries and outcome measures for our pharmaceutical and biotech partners to aid in fast and effective clinical trials.

The CMTA was founded by a patient, and to this day is powered by a community of patients who are all rallying behind our mission. With the largest constituency of CMT families around the world, the CMTA actively works with the patient community in the drug development process to ensure patients are our partners every step of the way.

The CMTA's overhead and financial management are best in class; more than 87% of every dollar goes directly to support our mission. We are also very proud that the CMTA has earned the top rating, 4 stars, by Charity Navigator and has a perfect 100% score for governance and transparency.

This is why STAR is the brightest beacon of hope in achieving our vision of a world without CMT.